erlotinib + dasatinib

Erlotinib + dasatinib is a combination of two small molecule tyrosine kinase inhibitors investigated primarily for the treatment of advanced non-small cell lung cancer (NSCLC). Erlotinib is an epidermal growth factor receptor (EGFR) inhibitor, while dasatinib inhibits Src family kinases and multiple other tyrosine kinases. The rationale for combining these agents stems from the frequent activation and cooperation between EGFR and Src signaling pathways in cancer, which can promote tumor growth, survival, invasion, and angiogenesis. Clinical studies have shown that this combination is tolerable with adverse effects consistent with each agent individually. Disease control rates around 59–63% were observed in NSCLC trials; however, significant clinical benefit was mainly seen in patients with activating EGFR mutations. The combination has not demonstrated sufficient efficacy to support its use in unselected NSCLC populations[1][2][3].

Other names

erlotinib hydrochloride